Can-Fite BioPharma Ltd. advances Namodenoson into Phase 2b pancreatic cancer testing. Discover what this means for immunotherapy economics.
Kallyope’s elismetrep migraine data point to a new TRPM8 treatment pathway. Find out what Phase 3 could prove next.
CervoMed Inc. reveals neflamapimod MRI data in DLB. Discover how biomarker-driven trials could reshape neurodegeneration drug development.
Can Alto Neuroscience’s ALTO-207 change treatment-resistant depression care? Read what the new Phase 2b trial could mean for psychiatry.
Nektar will discuss 52-week REZOLVE-AA data for rezpegaldesleukin on April 20. Find out what the alopecia areata catalyst could mean.
Longeveron Inc. publishes Phase 2b laromestrocel data in frailty. Explore what it means for stem cell therapy and regulatory next steps.
Kezar is seeking FDA alignment for zetomipzomib in autoimmune hepatitis. Find out what’s at stake for trial design, safety, and strategic alternatives.